(MedPage Today) — Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.
By week 72, participants on the dual GIP/GLP-1 receptor agonist tirzepatide lost 20.2% of body weight…
Source link : https://www.medpagetoday.com/endocrinology/obesity/115549
Author :
Publish date : 2025-05-12 19:57:00
Copyright for syndicated content belongs to the linked Source.
